Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer

Urology

Volumn 65, Issue 6, 2005, Pages 1146-1151

  Copp, Hillary ^a   Bissonette, Eric A ^a   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ORGANIZATION; PERINEUM; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIOISOTOPE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PALLADIUM; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES;

EID: 20444495333     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.12.014     Document Type: Article

References (30)

1. W.J. Catalona, D.S. Smith Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer intermediate-term results J Urol 160 1998 2428 2434
2. P.C. Walsh Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life a structured debate J Urol 163 2000 1802 1807
3. M. Ohori, M. Kattan, P.T. Scardino Radical prostatectomy for carcinoma of the prostate Mod Pathol 17 2004 349 359
4. M.J. Barry, P.C. Albertsen, M.A. Bagshaw Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management a retrospective analysis Cancer 91 2001 2302 2314
5. A.V. D'Amico, R. Whittington, S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
6. M.J. Zelefsky, K.E. Wallner, C.C. Ling Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer J Clin Oncol 17 1999 517 522
7. H. Ragde, L.J. Korb, A.A. Elgamal Modern prostate brachytherapy prostate specific antigen results in 219 patients with up to 12 years of observed follow-up Cancer 89 2000 135 141
8. N.N. Stone, R.G. Stock Prostate brachytherapy treatment strategies J Urol 162 1999 421 426
9. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
10. F.A. Critz, W.H. Williams, A.K. Levinson Simultaneous irradiation for prostate cancer intermediate results with modern techniques J Urol 164 2000 738 743
11. L.L. Kestin, A.A. Martinez, J.S. Stromberg Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer J Clin Oncol 18 2000 2869 2880
12. J. Laverdiere, J.L. Gomez, L. Cusan Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer Int J Radiat Oncol Biol Phys 37 1997 247 252
13. M.V. Pilepich, K. Winter, M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
14. M. Roach III, J. Lu, M.V. Pilepich Predicting long-term survival, and the need for hormonal therapy a meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627
15. M.V. Pilepich, R. Caplan, R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy report of Radiation Therapy Oncology Group protocol 85-31 J Clin Oncol 15 1997 1013 1021
16. T.R. Coblentz, E.A. Bissonette, K.R. Williams Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer early results in high risk patients Prostate Cancer Prostatic Dis 5 2002 219 225
17. L. Potters, R. Purrazzella, S. Brustein A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma Cancer 95 2002 1451 1456
18. A.V. D'Amico, Y. Wu, M.H. Chen Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer J Urol 165 2001 126 129
19. L.L. Kestin, N.S. Goldstein, F.A. Vicini Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy J Urol 168 2002 1994 1999
20. P.L. Ross, P.T. Scardino, M.W. Kattan A catalog of prostate cancer nomograms J Urol 165 2001 1562 1568
21. L.H. Sobin, C. Wittekind TNM Classification of Malignant Tumors 1997 John Wiley & Sons New York
22. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement guidelines for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041
23. F.A. Critz, W.H. Williams, C.T. Holladay Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques Urology 54 1999 968 971
24. D. Strauss, R. Shavelle An extended Kaplan-Meier estimator and its applications Stat Med 17 1998 971 982
25. M.J. Zhang Cox proportional hazards regression models for survival data in cancer research Cancer Treat Res 113 2002 59 70
26. J.F. Reed III A Monte Carlo investigation of the robustness of the Wald, likelihood ratio, and median tests with specified symmetric and asymmetric marginal distributions Comput Methods Progr Biomed 39 1993 131 136
27. F.A. Vicini, L.L. Kestin, A.A. Martinez The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer Int J Radiat Oncol Biol Phys 45 1999 553 561
28. R.J. Nejat, H.H. Rashid, E. Bagiella A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy J Urol 164 2000 1891 1894
29. Miller N, Smolkin ME, Bissonette E,, et al. Undetectable PSA at 6-12 months: a new marker for early success in hormonally treated patients following prostate brachytherapy. Cancer (in press).
30. A.V. D'Amico, R. Whittington, S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974